Latest News and Press Releases
Want to stay updated on the latest news?
-
Total Revenue for Q3 2021 was approximately $1.2 millionCash as of September 30, 2021, was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020Cash balance was further...
-
ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
-
Albert Weber to join OpGen as OpGen’s CFO effective January 1, 2022 from U.S.-German molecular diagnostics company EpigenomicsAnnounces inducement grant of 210,000 stock options under NASDAQ Listing...
-
ROCKVILLE, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter...
-
AREScloud is a new, commercial web application aimed at accelerating the analysis of sequenced clinical isolatesAREScloud offers an advanced solution for infection prevention and control ROCKVILLE,...
-
ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
-
ROCKVILLE, Md., Oct. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
-
Preliminary Total Revenue for Q3 2021 was approximately $1.2 millionCash as of September 30, 2021 was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020OpGen...
-
OpGen’s Acuitas® AMR Gene Panel allows testing for a comprehensive panel of 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogensAn aid to clinicians in the management of...
-
OpGen’s Unyvero Urinary Tract Infection (UTI) Panel tests for a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimensProspective multicenter trial...